1. Home
  2. AKRO vs STC Comparison

AKRO vs STC Comparison

Compare AKRO & STC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AKRO
  • STC
  • Stock Information
  • Founded
  • AKRO 2017
  • STC 1893
  • Country
  • AKRO United States
  • STC United States
  • Employees
  • AKRO N/A
  • STC N/A
  • Industry
  • AKRO Biotechnology: Pharmaceutical Preparations
  • STC Specialty Insurers
  • Sector
  • AKRO Health Care
  • STC Finance
  • Exchange
  • AKRO Nasdaq
  • STC Nasdaq
  • Market Cap
  • AKRO 3.7B
  • STC 2.1B
  • IPO Year
  • AKRO 2019
  • STC N/A
  • Fundamental
  • Price
  • AKRO $54.26
  • STC $69.74
  • Analyst Decision
  • AKRO Buy
  • STC Buy
  • Analyst Count
  • AKRO 10
  • STC 2
  • Target Price
  • AKRO $73.56
  • STC $77.50
  • AVG Volume (30 Days)
  • AKRO 4.2M
  • STC 195.7K
  • Earning Date
  • AKRO 11-07-2025
  • STC 10-22-2025
  • Dividend Yield
  • AKRO N/A
  • STC 3.01%
  • EPS Growth
  • AKRO N/A
  • STC 69.60
  • EPS
  • AKRO N/A
  • STC 3.60
  • Revenue
  • AKRO N/A
  • STC $2,796,713,000.00
  • Revenue This Year
  • AKRO N/A
  • STC $13.62
  • Revenue Next Year
  • AKRO N/A
  • STC $12.41
  • P/E Ratio
  • AKRO N/A
  • STC $19.38
  • Revenue Growth
  • AKRO N/A
  • STC 16.10
  • 52 Week Low
  • AKRO $21.34
  • STC $56.39
  • 52 Week High
  • AKRO $58.40
  • STC $78.44
  • Technical
  • Relative Strength Index (RSI)
  • AKRO 70.80
  • STC 44.52
  • Support Level
  • AKRO $53.40
  • STC $69.23
  • Resistance Level
  • AKRO $54.02
  • STC $75.50
  • Average True Range (ATR)
  • AKRO 0.28
  • STC 2.78
  • MACD
  • AKRO -0.06
  • STC -0.01
  • Stochastic Oscillator
  • AKRO 95.03
  • STC 25.79

About AKRO Akero Therapeutics Inc.

Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.

About STC Stewart Information Services Corporation

Stewart Information Services Corp is a customer-focused, title insurance and real estate services company offering products and services to home buyers and sellers, mortgage lenders and servicers, attorneys, and home builders. It has three operating segments; Title insurance and related services which generates key revenue, includes the functions of searching, examining, closing, and insuring the condition of the title to real property. It also includes home and personal insurance services, Real estate solutions segment supports the real estate mortgage industry by providing appraisal management services, online notarization and closing solutions, credit, and real estate information services, search and valuation services. Corporate and other segment is comprised of parent holding company.

Share on Social Networks: